Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens
| Autor: | Si-Yuan Hou, Kai-Lin Zhang, Dan Wu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Medicine (General) Psoriatic Arthritis Antibodies Monoclonal Humanized Severity of Illness Index law.invention Dactylitis Psoriatic arthritis R5-920 Randomized controlled trial Psoriasis Area and Severity Index law Internal medicine Medicine Humans Psoriasis Dosing Adverse effect Secukinumab Dosing Regimens business.industry Arthritis Psoriatic Antibodies Monoclonal General Medicine medicine.disease Rheumatology Treatment Outcome business Meta-Analysis |
| Zdroj: | Clinics, Vol 76 (2021) Clinics, Volume: 76, Article number: e2820, Published: 01 OCT 2021 |
| ISSN: | 1980-5322 |
| Popis: | The appropriate dosing regimens of secukinumab for psoriatic arthritis (PsA) are not well defined. We performed a meta-analysis to evaluate the efficacy and safety of different dosing regimens of secukinumab in the treatment of PsA. A systematic search was conducted using major electronic databases to identify relevant randomized controlled trials (RCTs) comparing secukinumab 300 mg versus secukinumab 150 mg in patients with PsA. Meta-analysis was performed using Review Manager software (version 5.3). Six studies with a total of 1141 patients were included. At week 24, secukinumab 300 mg was associated with a higher American College of Rheumatology 20% response (ACR 20), ACR 50, PASI 75 response rate, and dactylitis resolution rate than secukinumab 150 mg, especially in the anti-TNF-IR subgroup. At week 52, secukinumab 300 mg was associated with a higher psoriasis area and severity index (PASI) 75 and PASI 90 response rate than secukinumab 150 mg. There was no significant difference between secukinumab 300 mg and secukinumab 150 mg in the risk of any adverse events (AEs) and serious AEs at either week 24 or week 52. Secukinumab 300 mg was significantly more effective than 150 mg, especially for patients with PsA who have failed TNF therapy, and it was well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|